Mass Medical Angels
VC Fund
Boston, United States
Mass Medical Angels is a VC fund in Boston focused on Health Care and Biotechnology. Mass Medical Angels (MA2) was founded to answer the need for a dedicated life-science centric angel group in New England. The Boston area is a world-leading supercluster for medical innovation, but all early-stage companies in the field have tremendous difficulty with first round funding. Their goal is to provide money and mentoring to the lifescience community to achieve superior returns for their group, and more clinical innovation for the community.
- Total investments:
- 28
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Mass Medical Angels invests in
Stages Mass Medical Angels invests in
Countries Mass Medical Angels invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Health Care 14 (50%)
- Biotechnology 12 (43%)
- Medical Device 9 (32%)
- Medical 5 (18%)
- Therapeutics 4 (14%)
Stage
- Series A 8 (29%)
- Series B 7 (25%)
- Seed 6 (21%)
- Funding Round 1 (4%)
Country
- United States 16 (57%)
- Israel 1 (4%)
- Australia 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Penny Rossano
Chair - Screening
|
Chair - Screening | Total investments: 0 | Find email | |
Roger Kitterman
Vice President, Venture
|
Vice President, Venture | Total investments: 5 | Find email | |
David A. Fogel
Member / Member of Screening, Due Diligence Committees
|
Member / Member of Screening, Due Diligence Committees | Total investments: 0 | Find email | |
David Fogel
Member / Member of Screening, Due Diligence Committees
|
Member / Member of Screening, Due Diligence Committees | Total investments: 0 | Find email | |
Fred Mermelstein
Member
|
Member | Total investments: 0 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Entirety Biomedical
|
Magsorbeo Biomedical develops and manufactures absorbable metal implants with engineered absorption profiles. It uses its proprietary Curasorb alloy technology to safely minimize implant life post-healing, provide simple and confident implantation, and safely absorb without increased risks of long-term complications. | $1.2M / Seed / Feb 11, 2026 | |
Cayuga Biotech
|
Cayuga Biotech is a startup developing novel hemostatic drugs and devices to reduce uncontrollable bleeding which is a leading cause of death from traumatic injuries. The company's polyphosphate-based drug accelerates the body's own clotting process to contain clotting at the injury site and thus minimize the risk of side effects. Cayugais developing drugs for indications that treat traumatic hemorrhage as well as rare bleeding disorders. | $5M / Seed / Dec 11, 2025 | |
Astrocyte Pharmaceuticals
|
Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke,TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease. | $6M / Series B / Aug 18, 2023 | |
|
Astrocyte Pharmaceuticals
|
Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke,TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease. | $6M / Series A / May 03, 2021 | |
Coviu
|
Coviu is a telehealth startup that helps doctors and health practitioners with AI-backed clinical tools to make the video calling experience with the patient even better than actually seeing the patient in real life. The company offers consultations regarding cardiology, dentistry, dermatology, diabetes, dietetics, endocrinology, Endoscopy. generalpractice, beauty, naturopathy, nutrition, homeopathy, occupational therapy, child health and pediatrics, orthopedics, psychology, psychotherapy, plastic surgery, speech and language therapy, urology, women’s health, and many more.Its video consultations are enhanced with a range of in-call clinical tools, and its software integrates seamlessly with a range of practice management systems. | $6M / Series A / Dec 07, 2020 | |
Capillary Biomedical
|
Capillary Biomedical is a medical device startup developing technologies for diabetes management. They aim to dramatically simplify glucose monitoring and insulin delivery, reducing the burden on both patients and the overall healthcare system. The company is based in Irvine, CA and is a spin-out of the Artificial Pancreas Center at the SidneyKimmel Medical College of Thomas Jefferson University in Philadelphia, PA. | $2.9M / Seed / Aug 14, 2018 | |
Lantos Technologies
|
Lantos Technologies is the only FDA-cleared 3D ear scanning system that enables custom, in-ear products with superior comfort, sound quality, and performance. Our technology enables the efficient and effective delivery of customized hearing aids and other hearing-related products. | $10M / Mar 21, 2018 | |
|
Astrocyte Pharmaceuticals
|
Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke,TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease. | $2.4M / Seed / Jul 17, 2017 | |
Sentien Biotechnologies
|
Sentien Biotechnologies is a privately-owned, clinical-stage company developing novel cell therapies that restore balance to the immune system and transform treatment options for patients with systemic inflammatory diseases. The company's innovative blood conditioning approach has been proven to significantly enhance exposure and extendtherapeutic activity of Mesenchymal Stromal Cells (MSCs). By immobilizing MSCs in an extracorporeal device, their flagship SBI-101 product enables sustained, controlled dosage of secreted anti-inflammatory and regenerative properties that are unattainable by direct injection or intravenous infusion.Sentien Biotechnologies was established in 2008 and is headquartered in Lexington, Massachusetts, United States. | $12M / Series A / Apr 04, 2017 | |
InfoBionic
|
InfoBionic transforms the efficiency and the economics of ambulatory remote patient monitoring processes and cardiac diagnostic services by optimizing clinical and real-world utility for the users that need it most – physicians and their patients. It has developed the MoMe System, a remote patient monitoring platform initially focused on cardiacarrhythmia detection, to improve clinical efficiency and patient care with any time, anywhere access to patient data. The company was founded in 2011 and is headquartered in Waltham, Massachusetts. | $17M / Series B / Apr 08, 2014 | |
| See all 28 investments → | |||
Co-Investors
Boston Harbor Angels
12 deals together
LaunchPad Venture
8 deals together
Sidecar Angels
6 deals together
Beacon Angels
5 deals together
Cherrystone Angel Group
4 deals together
Maine Angels
4 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Mass Medical Angels invest in?
Mass Medical Angels invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series A and Series B stage. Most of the 28 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Mass Medical Angels?
Public channels for Mass Medical Angels include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Mass Medical Angels?
The team at Mass Medical Angels includes Penny Rossano (Chair - Screening), Roger Kitterman (Vice President, Venture) and David A. Fogel (Member / Member of Screening, Due Diligence Committees), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
